Coherus BioSciences is set to become the first company to offer biosimilars to Amgen’s complete range of Neulasta (pegfilgrastim) products, after obtaining approval from the US Food and Drug Administration for the company’s version of the Neulasta Onpro on-body injector device using Coherus’ Udenyca (pegfilgrastim-cbqv) biosimilar.
Coherus Eyeing US Pegfilgrastim Bulk With On-Body Injector Approval
Amgen’s Onpro Version Commands the >40% Of The US Market
Coherus has roared into the new year with a US FDA approval that has long been on its radar: the company’s debut rival to the Neulasta Onpro on-body injector device using Coherus’ Udenyca (pegfilgrastim-cbqv) biosimilar.
More from Products
• By
The elimination of the policy division at the Office of Generic Drugs, tariffs, the Section 232 investigation, and a new executive order to promote lower drug prices seem to both cause and purport to solve the same problem: supply chain disruption.
• By
Sunshine Biopharma is continuing to roll out generic launches in Canada, with its latest product challenging Afinitor and other everolimus rivals in the market.
• By
Celltrion’s adalimumab biosimilar was crowned as interchangeable by the FDA, at a time when the future of the designation is unknown.
• By
The challenging US biosimilar market remains a persistent problem, leading the biosimilar developer to reconsider how it invests in the future while pushing for changes.
More from Generics Bulletin
• By
After announcing the agreement last month, Xbrane has now approved its deal with Alvotech as part of an extra general meeting.
• By
Celltrion’s adalimumab biosimilar was crowned as interchangeable by the FDA, at a time when the future of the designation is unknown.
• By
The challenging US biosimilar market remains a persistent problem, leading the biosimilar developer to reconsider how it invests in the future while pushing for changes.